New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Identity and Independence: Many AYAs are in a developmental stage where they are gaining autonomy. A cancer diagnosis can ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

Despite the COVID-19 pandemic and related health care disruptions that caused a decrease in cancer incidence, overall cancer ...

AYA Cancer Awareness month offers an opportunity for nurses to go further in supporting AYAs with cancer.